ARTICLE | Product Development
Eli Lilly is among the companies pioneering alternative oncology endpoints to capture make-or-break nuances in data
By Lauren Martz, Executive Director, Biopharma Intelligence
November 3, 2023 9:47 PM UTC
At a time when the bar for safety and efficacy of new cancer drugs continues to rise, the ability to capture nuances in clinical data can be the difference between positive and negative results. That’s where novel endpoints such as treatment failure-free survival come into play.
Oncology has some of the industry’s most established clinical endpoints, and in many cases, overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) are still sufficient for evidence generation…